Cargando…

Treatment-related fluctuations in Guillain-Barré syndrome​: clinical features and predictors of recurrence

BACKGROUND: A treatment-related fluctuation (TRF) in a patient with Guillain-Barré syndrome (GBS) is defined as clinical deterioration within two months of symptom onset following previous stabilization or improvements with treatment. OBJECTIVE: To investigate the clinical characteristics and factor...

Descripción completa

Detalles Bibliográficos
Autores principales: ALESSANDRO, Lucas, CASTIGLIONE, Juan Ignacio, BRAND, Patricio, BRUNO, Veronica, BARROSO, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academia Brasileira de Neurologia - ABNEURO 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238334/
https://www.ncbi.nlm.nih.gov/pubmed/35195232
http://dx.doi.org/10.1590/0004-282X-ANP-2021-0226
_version_ 1784737027281911808
author ALESSANDRO, Lucas
CASTIGLIONE, Juan Ignacio
BRAND, Patricio
BRUNO, Veronica
BARROSO, Fabio
author_facet ALESSANDRO, Lucas
CASTIGLIONE, Juan Ignacio
BRAND, Patricio
BRUNO, Veronica
BARROSO, Fabio
author_sort ALESSANDRO, Lucas
collection PubMed
description BACKGROUND: A treatment-related fluctuation (TRF) in a patient with Guillain-Barré syndrome (GBS) is defined as clinical deterioration within two months of symptom onset following previous stabilization or improvements with treatment. OBJECTIVE: To investigate the clinical characteristics and factors that could increase the risk of relapse of GBS in patients with and without TRFs. METHODS: Retrospective review of medical records of patients (>18 years) with GBS evaluated between January/2006 and July/2019. Demographic and clinical characteristics, ancillary studies, treatment received, and the clinical course of patients with and without TRFs were analyzed. RESULTS: Overall, 124 cases of GBS were included; seven (5.6%) presented TRFs. GBS-TRF cases were triggered more frequently by infectious mononucleosis (28.57 vs. 8.55%; p=0.01). GBS-TRF were initially treated with plasmapheresis more frequently than those without TRF (14.29 vs. 1.70%; p=0.0349). Combined treatment (71.43 vs. 4.27%; p<0.001) and corticosteroids (42.86 vs. 1.71%; p<0.001) were more commonly used in the GBS-TRF group. GBS-TRF patients presented a higher median initial disability score (4 vs. 2; p=0.01). CONCLUSIONS: Patients with GBS triggered by infectious mononucleosis and a high degree of initial disability have higher chances of developing TRFs. Although patients with TRF were treated with plasmapheresis more often, the total number was too low to suggest a link between plasma exchange and TRF.
format Online
Article
Text
id pubmed-9238334
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Academia Brasileira de Neurologia - ABNEURO
record_format MEDLINE/PubMed
spelling pubmed-92383342022-12-08 Treatment-related fluctuations in Guillain-Barré syndrome​: clinical features and predictors of recurrence ALESSANDRO, Lucas CASTIGLIONE, Juan Ignacio BRAND, Patricio BRUNO, Veronica BARROSO, Fabio Arq Neuropsiquiatr Article BACKGROUND: A treatment-related fluctuation (TRF) in a patient with Guillain-Barré syndrome (GBS) is defined as clinical deterioration within two months of symptom onset following previous stabilization or improvements with treatment. OBJECTIVE: To investigate the clinical characteristics and factors that could increase the risk of relapse of GBS in patients with and without TRFs. METHODS: Retrospective review of medical records of patients (>18 years) with GBS evaluated between January/2006 and July/2019. Demographic and clinical characteristics, ancillary studies, treatment received, and the clinical course of patients with and without TRFs were analyzed. RESULTS: Overall, 124 cases of GBS were included; seven (5.6%) presented TRFs. GBS-TRF cases were triggered more frequently by infectious mononucleosis (28.57 vs. 8.55%; p=0.01). GBS-TRF were initially treated with plasmapheresis more frequently than those without TRF (14.29 vs. 1.70%; p=0.0349). Combined treatment (71.43 vs. 4.27%; p<0.001) and corticosteroids (42.86 vs. 1.71%; p<0.001) were more commonly used in the GBS-TRF group. GBS-TRF patients presented a higher median initial disability score (4 vs. 2; p=0.01). CONCLUSIONS: Patients with GBS triggered by infectious mononucleosis and a high degree of initial disability have higher chances of developing TRFs. Although patients with TRF were treated with plasmapheresis more often, the total number was too low to suggest a link between plasma exchange and TRF. Academia Brasileira de Neurologia - ABNEURO 2022-02-21 /pmc/articles/PMC9238334/ /pubmed/35195232 http://dx.doi.org/10.1590/0004-282X-ANP-2021-0226 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License
spellingShingle Article
ALESSANDRO, Lucas
CASTIGLIONE, Juan Ignacio
BRAND, Patricio
BRUNO, Veronica
BARROSO, Fabio
Treatment-related fluctuations in Guillain-Barré syndrome​: clinical features and predictors of recurrence
title Treatment-related fluctuations in Guillain-Barré syndrome​: clinical features and predictors of recurrence
title_full Treatment-related fluctuations in Guillain-Barré syndrome​: clinical features and predictors of recurrence
title_fullStr Treatment-related fluctuations in Guillain-Barré syndrome​: clinical features and predictors of recurrence
title_full_unstemmed Treatment-related fluctuations in Guillain-Barré syndrome​: clinical features and predictors of recurrence
title_short Treatment-related fluctuations in Guillain-Barré syndrome​: clinical features and predictors of recurrence
title_sort treatment-related fluctuations in guillain-barré syndrome​: clinical features and predictors of recurrence
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238334/
https://www.ncbi.nlm.nih.gov/pubmed/35195232
http://dx.doi.org/10.1590/0004-282X-ANP-2021-0226
work_keys_str_mv AT alessandrolucas treatmentrelatedfluctuationsinguillainbarresyndromeclinicalfeaturesandpredictorsofrecurrence
AT castiglionejuanignacio treatmentrelatedfluctuationsinguillainbarresyndromeclinicalfeaturesandpredictorsofrecurrence
AT brandpatricio treatmentrelatedfluctuationsinguillainbarresyndromeclinicalfeaturesandpredictorsofrecurrence
AT brunoveronica treatmentrelatedfluctuationsinguillainbarresyndromeclinicalfeaturesandpredictorsofrecurrence
AT barrosofabio treatmentrelatedfluctuationsinguillainbarresyndromeclinicalfeaturesandpredictorsofrecurrence